Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 5/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797401 | 1.00 | NOS1 (0.36) | NOS1NOS3NOS2GABRR1KMT2A | |
| SCHEMBL9417498 | 0.91 | CA12 (0.34) | NOS1NOS3NOS2GABRR1KMT2A | |
| SCHEMBL2177004 | 0.88 | CPB2 (0.38) | NOS1NOS3NOS2KMT2AMEN1 | |
| SCHEMBL133019 | 0.86 | CPB2 (0.44) | NOS1NOS3NOS2KMT2AMEN1 | |
| SCHEMBL2567893 | 0.85 | CPB2 (0.46) | NOS1NOS3NOS2KMT2AMEN1 | |
| SCHEMBL6799320 | 0.83 | NOS1 (0.35) | NOS1NOS3NOS2GABRR1KMT2A | |
| SCHEMBL5667907 | 0.83 | NOS1 (0.35) | NOS1NOS3NOS2GABRR1KMT2A | |
| Methylamine SCHEMBL28388761 | 0.82 | NOS1 (0.39) | NOS1NOS3NOS2KMT2AMEN1 | |
| SCHEMBL28058283 | 0.82 | KMT2A (0.36) | NOS1NOS3NOS2GABRR1KMT2A | |
| SCHEMBL9242626 | 0.81 | GPR84 (0.42) | NOS1NOS3NOS2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658668-A2 | OCCIDIOFUNGIN ANALOGS AND METHODS OF MAKING AND USING | The Texas A&M University System (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024163850-A2 | OCCIDIOFUNGIN ANALOGS AND METHODS OF MAKING AND USING | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-3873457-B1 | ISOSORBIDE-5-MONONITRATE DERIVATIVES AS POTENTIATORS OF VASODILATORY RELEASE OF NITRIC OXIDE IN HYPOXIA FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | COEURATIVE INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11779560-B2 | Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases | COEURATIVE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4126221-A2 | NOVEL METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | Coeurative, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115474429-A | Novel methods of treating COVID-19 and other infectious diseases using nitric oxide donor compounds | 合作股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20210346335-A1 | METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | COEURATIVE, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2021202317-A2 | NOVEL METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | COEURATIVE, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3873457-A1 | NOVEL COMPOUNDS USEFUL FOR TREATING CARDIOVASCULAR DISEASES | Coeurative, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113226301-A | Novel compounds suitable for the treatment of cardiovascular diseases | 科由拉特夫公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-1347784-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | Bristol-Myers Squibb Pharma Company (US) | 2003-10-01 | — | — | EP | disclosed |
| CN-1098278-C | Cinnamic acid derivative | SEIKAGAKU KOGYO CO LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
| CN-1090637-C | Crosslinked cinnamic acid hyaluronic acid derivatives and process for producing the same | SEIKAGAKU KOGYO CO LTD (JP) | 2002-09-11 | — | — | CN | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0713859-B1 | Cinnamic acid derivatives, photocrosslinkable cinnamic acid-polymer derivative and crosslinked cinnamic acid polymer derivatives | SEIKAGAKU KOGYO CO LTD (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-6107410-A | Cinnamic acid derivative | SEIKAGAKU CORPORATION (JP) | 2000-08-22 | — | — | US | disclosed |
| CN-1245812-A | Cinnamic acid derivative | SEIKAGAKU KOGYO CO LTD (JP) | 2000-03-01 | — | — | CN | disclosed |
| US-6025444-A | HYALURONIC ACID POLYSACCHARIDE DERIVATIVE; PHOTODIMERIZABLE, CROSSLINKABLE | SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) | 2000-02-15 | — | — | US | disclosed |
| CN-1133834-A | cinnamic acid derivatives | SEIKAGAKU KOGYO CO LTD (JP) | 1996-10-23 | — | — | CN | disclosed |
| EP-0713859-A2 | Cinnamic acid derivatives, photocrosslinkable cinnamic acid-polymer derivative and crosslinked cinnamic acid polymer derivatives | SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779560-B2 | Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
| US-20210346335-A1 | METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.